General Information of This Antibody
Antibody ID
ANTI0OYIZH
Antibody Name
XiRB49
Organization
Université Paris-Saclay.; INRAE.; Inria.; Université de Bourgogne.; Université Paris Cité.; Université Sorbonne Paris Nord.
Synonyms
xiRB49
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric lgG
Antigen Name
Endothelin-1 (EDN1)
 Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
XiRB49 MMAE [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.4&#1777.2 nM
Positive ET expression (ET+++/++)
Method Description
Cell cytotoxicity was monitored using a specific assay (Abcam, Cambridge, UK- Cat # 112118). This cytotoxicity assay is based on the measurement of mitochondrial dehydrogenase activity using a specific dye. This assay evaluates the metabolic activity of viable cells. Cells were plated at 1500 cells/well in 100 ul culture medium. The following day, 100 ul of increasing concentrations of mAb, diluted in culture medium, were added to each well. Cells were incubated for 96 h at 37 °C in a 5% CO2 incubator. The OD570/OD605 nm ratio was used to determine cell viability in each well in triplicate according to the instructions. Data were analyzed using Prism 9.4 (GraphPad Software San Diego, CA, USA) to determine the half maximal inhibitory concentration (IC50) using the variable slope model after checking that we had a normal distribution of these data by a D'Agostino & Pearson test.

   Click to Show/Hide
In Vitro Model Melanoma UACC-257 cells CVCL_1779
References
Ref 1 Targeting the activated allosteric conformation of the endothelin receptor B in melanoma with an antibody-drug conjugate: mechanisms and therapeutic efficacy